Parmar Dipali P, Bhole Pradnya K, Garde Pawan V
Department of Ophthalmology, M and J Institute of Ophthalmology (Government Eye Hospital), B. J. Medical College, Ahmedabad, Gujarat, India.
Oman J Ophthalmol. 2023 Feb 21;16(1):94-97. doi: 10.4103/ojo.ojo_2_22. eCollection 2023 Jan-Apr.
Rho-associated protein kinase inhibitor (ROCK) therapy for corneal endothelial dysfunction or damage other than glaucoma has been reported with few ocular side effects. We report reticular epithelial edema (REE) with netarsudil (0.02%) therapy in four cases with different clinical scenarios (three cases with corneal transplant and one case postcataract extraction). REE developed in all cases variably and cleared on cessation of netarsudil in three cases. One case was continued on netarsudil due to REE sparing the visual axis with no active ocular complaints. Partial clearance of stromal edema observed in all cases was correlated clinically to visual acuity considering existing comorbidities in an individual case.
据报道，Rho相关蛋白激酶抑制剂（ROCK）治疗除青光眼以外的角膜内皮功能障碍或损伤时，眼部副作用较少。我们报告了4例不同临床情况（3例角膜移植和1例白内障摘除术后）使用奈他地尔（0.02%）治疗出现网状上皮水肿（REE）的情况。所有病例均不同程度地出现了REE，3例在停用奈他地尔后水肿消退。1例因REE未累及视轴且无眼部不适症状而继续使用奈他地尔。考虑到个体病例中现有的合并症，所有病例中观察到的基质水肿部分消退与视力在临床上相关。
